Wouldn't being 3rd and 4th line of treatment likely result in lower mOS rate? Isn't mOS calculated from when they started leronlimab? I could imagine many of these women were grasping at anything at this point and some may have progressed too far for leronlimab to save....especially given lower dosage for many patients. Given the trial criteria, it seems mOS is not a good comparison to other trials given all the differences. It would be much more valuable and accurate information with similar screening criteria and larger size.

Hopefully the ESMO data includes a Kaplan-Meier curve and stratification by dose or treatment history.